These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 25692022)

  • 1. Components of the endocannabinoid and dopamine systems are dysregulated in Huntington's disease: analysis of publicly available microarray datasets.
    Laprairie RB; Bagher AM; Precious SV; Denovan-Wright EM
    Pharmacol Res Perspect; 2015 Feb; 3(1):e00104. PubMed ID: 25692022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Systematic Review of Transcriptional Dysregulation in Huntington's Disease Studied by RNA Sequencing.
    Malla B; Guo X; Senger G; Chasapopoulou Z; Yildirim F
    Front Genet; 2021; 12():751033. PubMed ID: 34721539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
    Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
    J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating the Transition of Pre-Symptomatic to Symptomatic Huntington's Disease Status Based on Omics Data.
    Christodoulou CC; Zachariou M; Tomazou M; Karatzas E; Demetriou CA; Zamba-Papanicolaou E; Spyrou GM
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33049985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
    Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
    Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systems Genetic Analyses Highlight a TGFβ-FOXO3 Dependent Striatal Astrocyte Network Conserved across Species and Associated with Stress, Sleep, and Huntington's Disease.
    Scarpa JR; Jiang P; Losic B; Readhead B; Gao VD; Dudley JT; Vitaterna MH; Turek FW; Kasarskis A
    PLoS Genet; 2016 Jul; 12(7):e1006137. PubMed ID: 27390852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.
    Moss DJH; Pardiñas AF; Langbehn D; Lo K; Leavitt BR; Roos R; Durr A; Mead S; ; ; Holmans P; Jones L; Tabrizi SJ
    Lancet Neurol; 2017 Sep; 16(9):701-711. PubMed ID: 28642124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Common disease signatures from gene expression analysis in Huntington's disease human blood and brain.
    Mina E; van Roon-Mom W; Hettne K; van Zwet E; Goeman J; Neri C; A C 't Hoen P; Mons B; Roos M
    Orphanet J Rare Dis; 2016 Aug; 11(1):97. PubMed ID: 27476530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis.
    Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J
    Elife; 2021 Apr; 10():. PubMed ID: 33871358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic cannabinoid receptor stimulation selectively prevents motor impairments in a mouse model of Huntington's disease.
    Pietropaolo S; Bellocchio L; Ruiz-Calvo A; Cabanas M; Du Z; Guzmán M; Garret M; Cho YH
    Neuropharmacology; 2015 Feb; 89():368-74. PubMed ID: 25123645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model.
    Laprairie RB; Bagher AM; Rourke JL; Zrein A; Cairns EA; Kelly MEM; Sinal CJ; Kulkarni PM; Thakur GA; Denovan-Wright EM
    Neuropharmacology; 2019 Jun; 151():1-12. PubMed ID: 30940536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cytokine and endocannabinoid systems are co-regulated by NF-κB p65/RelA in cell culture and transgenic mouse models of Huntington's disease and in striatal tissue from Huntington's disease patients.
    Laprairie RB; Warford JR; Hutchings S; Robertson GS; Kelly ME; Denovan-Wright EM
    J Neuroimmunol; 2014 Feb; 267(1-2):61-72. PubMed ID: 24360910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo models of Huntington's disease show alterations in the endocannabinoid system.
    Bari M; Battista N; Valenza M; Mastrangelo N; Malaponti M; Catanzaro G; Centonze D; Finazzi-Agrò A; Cattaneo E; Maccarrone M
    FEBS J; 2013 Jul; 280(14):3376-88. PubMed ID: 23659592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated Bioinformatics Analysis of Shared Genes, miRNA, Biological Pathways and Their Potential Role as Therapeutic Targets in Huntington's Disease Stages.
    Christodoulou CC; Papanicolaou EZ
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysregulation of the Basal Ganglia Indirect Pathway in Early Symptomatic
    Callahan JW; Wokosin DL; Bevan MD
    J Neurosci; 2022 Mar; 42(10):2080-2102. PubMed ID: 35058372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A common gene expression signature in Huntington's disease patient brain regions.
    Neueder A; Bates GP
    BMC Med Genomics; 2014 Oct; 7():60. PubMed ID: 25358814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioinformatic gene analysis for potential therapeutic targets of Huntington's disease in pre-symptomatic and symptomatic stage.
    Xiang C; Cong S; Liang B; Cong S
    J Transl Med; 2020 Oct; 18(1):388. PubMed ID: 33054835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysregulation of gene expression in primary neuron models of Huntington's disease shows that polyglutamine-related effects on the striatal transcriptome may not be dependent on brain circuitry.
    Runne H; Régulier E; Kuhn A; Zala D; Gokce O; Perrin V; Sick B; Aebischer P; Déglon N; Luthi-Carter R
    J Neurosci; 2008 Sep; 28(39):9723-31. PubMed ID: 18815258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential proteomic and genomic profiling of mouse striatal cell model of Huntington's disease and control; probable implications to the disease biology.
    Choudhury KR; Das S; Bhattacharyya NP
    J Proteomics; 2016 Jan; 132():155-66. PubMed ID: 26581643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compromised Dopaminergic Encoding of Reward Accompanying Suppressed Willingness to Overcome High Effort Costs Is a Prominent Prodromal Characteristic of the Q175 Mouse Model of Huntington's Disease.
    Covey DP; Dantrassy HM; Zlebnik NE; Gildish I; Cheer JF
    J Neurosci; 2016 May; 36(18):4993-5002. PubMed ID: 27147652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.